Because autoantibodies appear early in the course of disease, they can be used to establish disease-specific signatures to aid in early detection. Predictive signatures can be established to identify a disease state, sometimes before the patient begins to experience symptoms.

Autoantibody signatures can also play an important role in ensuring patients receive the right treatments. Development of companion diagnostics (CDx) helps safeguard patients by ensuring only those who will benefit from a drug will be treated with it.

Having the ability to interrogate many autoantibody targets in a single assay can help accelerate the identification and validation of signatures with high predictive value.

Accelerating discovery of autoantibody signatures

Sengenics can help, with solutions to support discovery of biomarker signatures. Our high-density protein microarray assays enable highly specific and reproducible detection of disease-relevant autoantibodies directly from patient serum.

Related Study

Candidate Autoantibody Biomarkers for Anti-drug Antibodies in RA Patients

Candidate autoantibody biomarkers for the prediction of anti-drug antibody (ADAb) development in adalimumab treated rheumatoid arthritis patients. Heat map of autoantibody presence and hierarchical clustering for the presence or absence of anti-drug antibody and clinical response. Plasma samples were taken at baseline and post 24 weeks of adalimumab therapy. Autoantibody levels were measured in RFU and are represented on a color scale.​

Source: Chen, P., et. al., Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA, Journal of Immunology Research (2021).

Ready to accelerate your program?